Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;37(5):101784.
doi: 10.1016/j.beem.2023.101784. Epub 2023 May 10.

Management of non-hepatic distant metastases in neuroendocrine neoplasms

C Lacalle-González  1 , A Estrella Santos  2 , L C Landaeta Kancev  3 , V M Castellano  4 , E Macia Palafox  5 , A Paniagua Ruíz  6 , J Luna Tirado  7 , B Martínez-Amores  8 , L Martínez Dhier  9 , A Lamarca  10
Affiliations
Review

Management of non-hepatic distant metastases in neuroendocrine neoplasms

C Lacalle-González et al. Best Pract Res Clin Endocrinol Metab. 2023 Sep.

Abstract

Neuroendocrine neoplasms represent an uncommon disease with an increasing incidence. Thanks to improvements in diagnostic and therapeutic methods, metastases previously considered uncommon, such as bone metastases, or even very rare, such as brain, orbital and cardiac metastases, are more frequently found in daily practice. Due to the great heterogeneity of these neoplasms, there is a lack of high-quality evidence on the management of patients with these types of metastases. The aim of this review is to provide the current state of the art, reviewing neuroendocrine neoplasm specific studies and useful information from other tumor types and to propose a treatment recommendation with algorithms to consider in daily clinical practice.

Keywords: Brain metastases; bone metastases; cardiac metastases; neuroendocrine tumor; orbital metastases; review.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement L-G C, E A, L LC, C VM, M E, P A, L J, M B and M L have no conflict of interest to declare. L A declares travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan and Delcath; speaker honoraria from Merck, Pfizer, Ipsen, Incyte, AAA, QED, Servier, Astra Zeneca, EISAI, Roche and Advanz Pharma; advisory and consultancy honoraria from EISAI, Nutricia Ipsen, QED, Roche, Servier, Boston Scientific, Albireo Pharma, AstraZeneca, Boehringer Ingelheim, GENFIT, TransThera Biosciences and Taiho; she is also a member of the Knowledge Network and NETConnect Initiatives funded by Ipsen.

Publication types

LinkOut - more resources